Portfolio

Our activities as strategic adverse event researchers & trainers date back to the late 1990's. At that time, researching and teaching effective step-by-step measures about turnaround the non-toxic adverse events from targeted anti-cancer therapies was not commonplace. In fact, we were the first to assume this role. As a result, we have grown to become one of the most experienced adverse event experts globally. Over time, we have raised a suite of curricula that target stakeholders who deal on a daily base with targeted anticancer therapies, the latest two being COSTA and CMSI. With our 6-TARGET-step approach we have an average adverse event turnaround rate of 98%, making it the most effective approach worldwide.